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Introduction
Chronic allograft nephropathy (CAN) is the principle cause of late graft loss after the first year of renal transplantation (1) , accounting for 50-80% of graft losses after this time (2) .
The reasons for this are multi-factorial including immune and non-immune factors e.g. acute rejection (3, 4) , delayed graft function (5) and acute calcineurin-inhibitor toxicity (6, 7) . Also, despite the significant improvement in the rate of acute renal rejection over the last decade (8) , CAN remains the leading cause of late graft lost after renal transplantation (9) .
At present, a histological diagnosis with a renal transplant biopsy is the 'gold standard' for determining CAN. CAN is a descriptive term for histological lesions in a renal allograft that include atherosclerosis, glomerulosclerosis, interstitial fibrosis, and tubular atrophy (10) . This has been a challenging disorder to diagnose by alternative and less invasive means in so far as it has a multi-factorial aetiology (11) . As in the case of acute renal transplant rejection, there is growing consensus that such complex and heterogeneous processes could best be fingerprinted using a pattern of collectively and individually informative biomarkers (12) .
Proteomic approaches have recently been employed towards this end. Surfacedenhanced laser-desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) is a technique that addresses some of the limitations of both two-dimensional gel electrophoresis (2-DE) and liquid chromatography mass spectrometry (LC-MS). This SELDI approach allows for high-throughput profiling of multiple clinical samples.
Multiple studies have revealed the feasibility of developing this technology for biomarker discovery (13) for the early detection of diseases including ovarian cancer (14, 15) , breast cancer (16) and prostate cancer (17, 18) . Three separate investigative groups have recently described changes in urinary protein excretion in transplant patients with biopsy-proven acute rejection (19, 20, 21) . However, to our knowledge there have been no published studies investigating CAN using SELDI-TOF-MS (22, 23) .
Although any biologic fluid may be examined in the search for biomarkers by SELDI-TOF-MS (24, 25) , the overriding principle is the simplicity of obtaining such a material for diagnostic purposes. In the case of CAN, the obvious choice of diagnostic material is the urine, a biologic fluid that potentially is most reflective of pathologic events that take place in the kidney. A non-invasive biomarker of rejection may benefit the kidney allograft recipient by allowing frequent monitoring to optimise immunosuppressive therapy.
Using SELDI to determine the urinary protein profiles associated with CAN, it could be possible to predict individuals susceptible to its development by non-invasive means compared to the very invasive current investigative tool of the renal biopsy (26) .
Therefore, the overall purpose of this study was to examine urine from renal transplant patients with documented CAN and also normal renal function using proteomic techniques in order to identify potential novel biomarker patterns for detecting CAN.
Identification of non-invasive biomarkers or a biomarker pattern of CAN would benefit the kidney allograft population by allowing frequent monitoring to optimise immunosuppressive therapy thus preventing disease progression. were identified and asked to participate in the study if they met the inclusion criteria.
Materials and methods

Study population and sample collection:
Clinical and historical data were documented for each patient including age, gender and immunosuppression regimen which typically included a calcineurin inhibitor (cyclosporine with trough level 50 to 150 ng/ml or tacrolimus with trough level 5 to 10 ng/ml or sirolimus with trough level 10 to 15 ng/ml), an antimetabolite (either azothioprine or mycophenolate mofetil) and prednisolone.
All patients completed a consent form for urine collection and for release of clinical data in accordance with the Control of Clinical Trials Act 1987 and 1990 and the European Guidelines of Good Clinical Practice and the protocols. Mid-stream urine specimens were collected from each patient after urinalysis confirmed the absence of a urinary tract infection. Samples were immediately placed on ice and transported to the laboratory in less than 4 hours (19, 27) . The urine samples were centrifuged at 4000G for 10 minutes at 4 O C and supernatants were immediately frozen in liquid nitrogen prior to storage at -80 O C until further analysis.
Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS):
Urine samples were thawed on ice, centrifuged for 10 minutes at 4000G and protein concentrations were estimated by the bicinchoninic acid kit (BCA) method (Pierce). 160 μl of the urine sample was added to 60 μl of U9 buffer (9M urea, 2% CHAPS, and 50 mM Tris (pH9)) to denature the proteins. The samples were applied in duplicate to weak cation exchange (CM10 ProteinChip TM ), immobilised metal affinity (IMAC30 ProteinChip TM ) and reverse phase ProteinChip arrays (H50 ProteinChip TM ) (Ciphergen Biosystems, Freemont, CA) according to the manufacturer's protocol. This process has been described previously (19, 28, 29) .
Peak detection was performed using ProteinChip Software version 3.2 (Ciphergen Biosystems); peaks were identified using a signal-to-noise ratio of >5. Baseline subtraction was performed on all spectra, and the data were normalised using total ion current.
Data analysis:
The data obtained from the ProteinChip Software was exported into CiphergenExpress Software version 3.0 (Ciphergen Biosystems). This software generated clustered peaks and analyzed the peak clusters using P-value calculation, receiver operator characteristic (ROC) plots, and principal component analysis (PCA). This cluster data was then exported to Biomarker Pattern Software (BPS) version 5.0.2 (Ciphergen Biosystems).
BPS used Classification and Regression Trees (CART) to analyze the proteins
and samples with respect to disease background. BPS analysis split each node into a classification tree and assigning each terminal node a predicted value. The splitting decisions were based on the normalised intensity levels (height) of peaks from the SELDI protein expression profile. The data was analyzed using 10-fold cross-validation, i.e., a model was constructed on 90% of the data and then tested on the remaining 10%. This analysis was performed 10 times.
2.4
Purification of the protein peak clusters: interest at the appropriate molecular weight was then excised, trypsinised and prepared for further characterisation by mass spectrometry.
Identification of the protein peak clusters by Liquid Chromatography (LC)
Tandem mass spectrometry:
Mass spectrometry was performed on the selected trypsinised gel fragments using a LTQ mass spectrometer (ThermoFinnegan) which was described previously (29) . The identified peptides were compared to amino acid sequences from the human IPI protein database (http://www.ebi.ac.uk/IPI/IPIhelp.html) (30,31,32).
Verification of protein peak cluster identity:
Further confirmation was needed to verify that the purified protein peak identified in the initial study CAN urine samples had exactly the same protein peak by SELDI-TOF-MS as the purified protein. This was performed by comparing a commercially available purified protein and the CAN urine sample on a CM10 ProteinChip.
2.7
Quantification of the identified protein: Whitney test (rank sum test) which did not assume a Gaussian distribution was conducted. Two-tailed p values were calculated with 95% confidence intervals.
Results
Patient characteristics:
In this retrospective study, the 'disease' group included 34 
Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS):
A total of 344 protein peaks were identified after SELDI analysis of all samples. The SELDI-TOF-MS spectra of protein peaks, obtained with CM10 ProteinChips at the three molecular weight ranges (described in Figure 1A ), showed differential regulation of multiple protein peaks in both the control and CAN patient samples (Figure 1 B-D) .
Consequently, statistical and bioinformatics analyses were used to determine whether potential biomarkers of CAN were present in the spectra.
Data analysis:
Spectra generated by SELDI-TOF-MS were exported to Ciphergen Express Software for normalization, calibration, peak identification and clustering of related peaks. This clustered data was then exported to Biomarker Patterns Software (BPS), which was used to search for significant relationships using Classification and Regression Trees (CART).
The classification tree with the greatest specificity and sensitivity was tree number 2 which was chosen for further analysis (Figure 2 ). This tree contained 7 nodes or proteins, which together made up a biomarker pattern for distinguishing CAN compared from normal transplant controls. This particular tree had a high sensitivity (80.30%) and specificity (67.65%) for predicting CAN compared to normal transplant controls (receiver operating characteristic (ROC) = 0.996). The primary node identified in this tree had a m/z: 11724.0 Da (primary node, and therefore the key protein of the tree).
Identification of the protein peak clusters:
Due to the relative importance of this tree in differentiating between CAN and control patients, the 11.7 kDa primary node protein of this tree was chosen as a target for identification. The optimum urine fraction underwent 1-D SDS-PAGE and was stained with Coomassie Blue stain. The band of interest (at 11.7 kDa) was then excised, trypsinised and prepared for mass spectrometry. This 11.7 kDa band was identified as β2 microglobulin with an overall probability score using the ProteinProphet software tool of 1. Two unique peptides were identified from the human β2 microglobulin sequence. The mass spectrum data obtained, together with the peptide sequences and the full protein sequence for β2 microglobulin are displayed in Figure 3 . Attempts were made to identify the other members of the biomarker pattern but isolating sufficient quantity and quality of these proteins proved to be too difficult.
Verification and quantification of the identified protein:
Commercially available purified human β2 microglobulin protein (Serotec) was used to verify that the protein peak identified was indeed β2 microglobulin. Purified human β2 microglobulin applied to a CM10 ProteinChip together with pooled CAN urine and the resultant spectra were compared after SELDI-TOF-MS was performed. Figure 4 A displays that the 11.7 kDa peak identified as β2 microglobulin by tandem MS, was the 11.7 kDa protein peak seen in the original urine samples.
Using a β2 microglobulin ELISA, a significant difference in the β2 microglobulin concentrations was demonstrated between the CAN group and the normal transplant control group as shown in Figure 4 B (33, 19, 20, 21) . In fact, Schaub et al identified β2 microglobulin as a potential biomarker for acute renal transplant rejection (33) .
Several potential biomarkers for CAN have been reported in the past including retinol binding protein (34) , transforming growth factor beta (35) and alpha-1 microglobulin (36) but there have not been any urinary biomarker patterns or biomarker proteins identified with SELDI-TOF-MS analysis for CAN.
The optimal biomarker pattern resulted from the CM10 ProteinChip had the highest sensitivity and specificity (ROC 0.996) compared to the biomarker patterns obtained from IMAC30 or H50 ProteinChips (ROC 0.974 and 0.937 respectively). For this reason, the CM10 ProteinChip biomarker pattern was chosen for further characterisation in this study. Importantly even without identifying all of the protein peaks, the classification tree can be used to distinguish CAN from controls with a relatively high degree of certainty. However the identification of these proteins would undoubtedly be advantageous and could potentially provide a better insight into CAN and may be of diagnostic use in a clinical setting. As the principle node of the biomarker pattern tree, the 11.7 kDa M/Z protein was of particular interest. Individually, this protein was a significant disease marker (p=0.001; ROC 0.774). By employing several confirmatory experiments including SELDI-TOF-MS of purified β2 microglobulin which had an identical protein peak at 11.7 kDa when compared to the urine of CAN patients, the 11.7 kDa protein was identified as β2 microglobulin. Significantly higher concentrations of β2 microglobulin were observed in the urine of patients with CAN compared to controls. β2 microglobulin is a 99 amino acid protein and is found on the cell surface of all nucleated cells. On average, 150-250 mg/day of β2 microglobulin is produced in normal individuals (37) . Normally, β2 microglobulin is shed from the cell surface, circulates in the serum (98% as a free form) and this serum level depends on glomerular function.
Most free β2 microglobulin is filtered by the glomeruli and more than 99.9% is reabsorbed by the proximal tubular cells where it is degraded into peptides or amino acids by lysosomes before reuptake into the circulation (38) . In healthy people, <0.2 mg/l of β2 microglobulin is excreted daily in the urine in the presence of normal proximal tubular function (39) .
Thus, β2 microglobulin is a good urinary biomarker to assess proximal tubular function. β2 microglobulin has been identified previously as a marker of other diseases e.g. tubulointerstitial disease (40) , acute renal transplant rejection (33) , drug toxicity (41), autoimmune diseases (42, 43) and lymphoproliferative diseases (44, 45) . As β2 microglobulin is a good urinary biomarker to assess proximal tubular function, this may explain why along with the accompanying biomarker tree it is a significant biomarker in this study due to the tubulointerstitial injury present in CAN. However, this study has some limitations, protocol renal transplant biopsies were not carried out at our centre and therefore the number of CAN patients in the study with mild (Banff Grade 1) CAN was very small. A limitation of this study is that more control groups were not included, e.g.
patients with urinary tract infections, acute tubular necrosis (20) . However such comparison groups have transient or acute urinary changes which would not have been captured with the retrospective methodology of our study. A larger cohort of patients would be required to confirm whether β2 microglobulin is specific for CAN or simply indicates tubular injury. An expanded study would provide insight into whether the detection of biomarkers such as β2 microglobulin would be clinically relevant in the diagnosis of CAN.
To summarise, this study has identified a novel urinary biomarker, β2
microglobulin, that can differentiate between transplant patients with CAN and those with normal renal function. We have also identified a key protein of this classification tree as β2 microglobulin. Further work is required to validate these markers in a more diverse patient population, in order to determine their true clinical diagnostic and prognostic value. (Figure 1 A) .
Representative SELDI-TOF mass spectra comparing CAN urine to control urine are shown at three different molecular weight (MW) ranges on CM10 ProteinChips (Figure 1 B-D). Mass-to-charge ratio (m/z) is along x -axis and relative intensity is along y -axis.
The corresponding computer-generated gels are views of the same spectra (right). 
